Novel cell wall synthesis inhibitors with appended siderophores have:

• Improved penetration into and growth inhibition of Gr- bacteria
• Decreased susceptibility betalactamases; avoiding a major cause of resistance
• Expanded spectrum of inhibition
• Concise modular synthesis
• Do not contain a beta-lactam ring, decreasing likelihood of allergic response
• Superior potency vs clinical isolates when compared to ceftazidime, imipenem, etc.
• IP status: PCT/US2019/042643
• Lead Innovator: Mark Plummer, PhD